Illumina Says IP Suit Ruling 'Unfortunate,' Will Continue Trying to Invalidate Affy IP | GenomeWeb
Hitting the road after suffering a setback in an ongoing patent dispute with Affymetrix, Illumina CEO Jay Flatley told investors at two conferences last week that the official outcome in the case is “insufficiently determinable” and said the firm will try to invalidate the IP at the heart of the dispute.
 
The company will also try to prove that Affymetrix is guilty of inequitable conduct, unfair competition, and of violating US anti-trust regulations.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.